The Orphan Drug Act and rare cancers: a retrospective analysis of oncologic orphan drug designations and associated approvals from 1983-2022

Abraham Viju Ipea Pediatrics, Children’s National Hospital, Washington DC, USAView further author information

Lewis J. Fermaglichb Office of Orphan Products Development, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USACorrespondence[email protected]
View further author information

Selma Kraftb Office of Orphan Products Development, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USAView further author information

Catherine Measeb Office of Orphan Products Development, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USAView further author information

Tran Leb Office of Orphan Products Development, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USAView further author information

Kathleen L. Millerc Division of Science and Public Health Policy, Office of Science and Data Policy, Office of the Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services, Washington DC, USAView further author information

The Orphan Drug Act and rare cancers: a retrospective analysis of oncologic orphan drug designations and associated approvals from 1983-2022

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The Orphan Drug Act and rare cancers: a retrospective analysis of oncologic orphan drug designations and associated approvals from 1983-2022

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date